Explore our brands

Our brands bring together the industry's most influential leaders and scientific experts, inspiring thought-provoking and insightful content that offers a unique perspective on R&D trends and challenges.
Contact

Resources

The latest in immuno research, from the discovery & development of cell & antibody therapies through to omics-based approaches and clinical case studies

Top R&D Stories of 2023

Through captivating articles, insight pieces, and spotlight interviews, we delve into the remarkable innovations, breakthroughs, and scientific marvels that have defined the landscape of research over the past year.
Read Now
Translational & Preclinical Development

Rockland Custom Services

Read More
Translational & Preclinical Development

Host Cell Protein & Bioprocessing Reagent Development - Rockland

Read More
Therapeutic Modalities

The Challenges Facing Antibody-Drug Conjugates for Immuno-Oncology

The targeted cancer therapy has made recent clinical and market breakthroughs, but what are the next hurdles for ADCs?
Read More
Therapeutic Modalities

Immuno Oncology Investigations: The NKG2D Pathway, Diagnostic Biomarker, and Allogenic CAR Ts

Cell UK 2021 hosts experts in cell and immunotherapy working towards new diagnostic tools and therapies.
Read More
Therapeutic Modalities

Express Your Cells: Enhancing T Cell Function with Small Molecule HPK1 Inhibitors

Inhibiting the HPK1 pathway can enhance the cancer killing function of T lymphocytes. RAPT Therapeutics showcases a series of small molecules to do this.
Read More
Therapeutic Modalities

iNKT Cells and Their Applications in Immuno-Oncology

The applications of iNKT cells as oncological therapeutics and remedial treatments are almost astoundingly diverse. Their capacity for moderation subject to their intended use makes them suited to a variety of therapeutic functions and applications.
Read More
Translational & Preclinical Development

Preclinical Strategies for Combination Immunotherapies

Oncology is almost always oriented towards simultaneous treatment options. We explore why as well as the approach’s unique challenges.
Read More
Translational & Preclinical Development

AAV Gene Therapy and CAR T Therapies: Immunogenicity and Immunoassay Development

Dr. Vibha Jawa, Executive Director, Nonclinical Disposition and Bioanalysis at BMS
Read More
Therapeutic Modalities

Addressing Immunotherapy Resistance Through PVRIG And TIGIT Blockade

In this interview, Eran Ophir discusses Compugen's exciting approach to immune checkpoint inhibitors for the treatment of cancer and what makes them stand out from the crowd.
Read More
Therapeutic Modalities

Using Live Gut Bacteria as a Co-Therapy for Checkpoint Inhibitors

Microbiotica’s live bacterial therapeutic is currently manufacturing for phase Ib trials in 2023.
Read More
Therapeutic Modalities

Microbiome Solutions to Immuno-Oncology Problems

Investigating the role of the microbiota in checkpoint inhibitor response.
Read More
Translational & Preclinical Development

Investigating the Core Tenet of Immunotherapy: MHC-I Peptide-Receptor Complexes

Axel Ducret, a Roche Senior Principal Scientist, takes us through his work on one of the most important cellular mechanisms in immunotherapy.
Read More

Subscribe to Our Newsletter

Sign up for our monthly newsletter to
keep up with all things immuno